Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Eric Seifter, Saad Z. Usmani
Publikováno v:
Hematology. 2018:97-102
Mrs. K is a 62-year-old woman who notes a 6-month history of worsening midthoracic back pain with marginal relief from increasing doses of ibuprofen. She is a school librarian working in a rural community and married, with 3 children out of the house
Autor:
Christopher Chiu, Hugo Ceulemans, Torben Plesner, Greet Vanhoof, Jordan M. Schecter, Nizar J. Bahlis, Saad Z. Usmani, Tina Smets, Homer Adams, Andrew C. Lysaght, Yann Abraham, Hervé Avet-Loiseau, Jaime Bald, Frederik Stevenaert, Joshua Rusbuldt, Karl C. Nielsen, Amy Axel, Tuna Mutis, Tineke Casneuf, Inger S. Nijhof, Koen Van der Borght, Brad Foulk, Niels W.C.J. van de Donk
Publikováno v:
Casneuf, T, Adams, H C, van de Donk, N W C J, Abraham, Y, Bald, J, Vanhoof, G, Van der Borght, K, Smets, T, Foulk, B, Nielsen, K C, Rusbuldt, J, Axel, A, Lysaght, A, Ceulemans, H, Stevenaert, F, Usmani, S Z, Plesner, T, Avet-Loiseau, H, Nijhof, I, Mutis, T, Schecter, J M, Chiu, C & Bahlis, N J 2021, ' Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab ', Leukemia, vol. 35, no. 2, pp. 573-584 . https://doi.org/10.1038/s41375-020-0855-4
Leukemia
Leukemia, 35(2), 573-584. Nature Publishing Group
Casneuf, T, Adams, H C, van de Donk, N W C J, Abraham, Y, Bald, J, Vanhoof, G, Van der Borght, K, Smets, T, Foulk, B, Nielsen, K C, Rusbuldt, J, Axel, A, Lysaght, A, Ceulemans, H, Stevenaert, F, Usmani, S Z, Plesner, T, Avet-Loiseau, H, Nijhof, I, Mutis, T, Schecter, J M, Chiu, C & Bahlis, N J 2021, ' Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab ', Leukemia, vol. 35, pp. 573-584 . https://doi.org/10.1038/s41375-020-0855-4
Leukemia
Leukemia, 35(2), 573-584. Nature Publishing Group
Casneuf, T, Adams, H C, van de Donk, N W C J, Abraham, Y, Bald, J, Vanhoof, G, Van der Borght, K, Smets, T, Foulk, B, Nielsen, K C, Rusbuldt, J, Axel, A, Lysaght, A, Ceulemans, H, Stevenaert, F, Usmani, S Z, Plesner, T, Avet-Loiseau, H, Nijhof, I, Mutis, T, Schecter, J M, Chiu, C & Bahlis, N J 2021, ' Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab ', Leukemia, vol. 35, pp. 573-584 . https://doi.org/10.1038/s41375-020-0855-4
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natura
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6476f20835a97bd61e5db396f8b77608
https://research.vumc.nl/en/publications/534ff20f-4ef5-47f0-a75d-98f650c178d0
https://research.vumc.nl/en/publications/534ff20f-4ef5-47f0-a75d-98f650c178d0
Publikováno v:
The Lancet. Haematology. 8(6)
Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory domain (eg, CD28 or 4-1BB [TNFRSF9, also known as CD137]). The B-cell matur
Autor:
Clarissa M. Uhlar, Jesús F. San-Miguel, Lotfi Benboubker, Saad Z. Usmani, Maria-Victoria Mateos, Alfred L. Garfall, Hareth Nahi, Rachel Kobos, Philippe Moreau, Rian Van Rampelbergh, Britta Besemer, Amrita Krishnan, Lionel Karlin, Jenna D. Goldberg, Laura Rosiñol, Suzette Girgis, Joaquin Martinez-Lopez, Nizar J. Bahlis, Niels W.C.J. van de Donk, Ajay K. Nooka, Albert Oriol, Lixia Pei, Thomas Martin, Arnob Banerjee, Raluca Verona, Yunsi Olyslager, Mindy Jaffe, Ajai Chari, Danielle Trancucci, Surbhi Sidana, Tara Stephenson, Rakesh Popat
Publikováno v:
Blood. 138:896-896
Introduction: Teclistamab (JNJ-64007957) is a T-cell redirecting, bispecific IgG4 antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. Teclistamab is un
Autor:
Saad Z. Usmani
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S161
Over the past five years, several antibody-based therapeutic approaches have been investigated in multiple myeloma (MM) beyond the naked antibodies that had targeted DKK1, CD38 and SLAMF7. The antibody-drug conjugates (ADCs) have been utilized for di
Publikováno v:
Leukemia. 29:2119-2125
Multiple myeloma (MM) is more recently being recognized as a heterogeneous group of disease with variability in outcomes based on specific clinical and biologic predictors. MM patients can be broadly categorized into standard, intermediate and high r
Autor:
Frits van Rhee, Regina Lichti Binz, Maurizio Zangari, Jeffrey R. Sawyer, Saad Z. Usmani, Bart Barlogie, Angela Boast, Sarah Waheed, Erming Tian, Janet L. Lukacs, Charles M. Swanson, Joshua Epstein, Donald J. Johann, Christoph Heuck, Gael Sammartino, Marian Johnson
Publikováno v:
Blood. 123:2504-2512
Multiple myeloma (MM) is a B-cell malignancy driven in part by increasing copy number alterations (CNAs) during disease progression. Prognostically significant CNAs accumulate during clonal evolution and include gains of 1q21 and deletions of 17p, am
Autor:
Fei Guo, Saad Z. Usmani, Elise Tjaden, Alicia Hamilton, Ami Ndiaye, James T. Symanowski, Peter M. Voorhees, David M. Foureau, Manisha Bhutani, Laura Lee Johnson, Nury Steuerwald, Shebli Atrash, Marina Leonidas, Sally Trufan, Katherine Rigby, Jordan Williams, Aarin Berlin
Publikováno v:
Blood. 132:4461-4461
INTRODUCTION: Progression from precursor states, MGUS and smoldering multiple myeloma (SMM), to multiple myeloma (MM) is dependent upon adaptive and innate immune contexture shaped by cross-talk between malignant plasma cells and bone marrow (BM) mil
Autor:
Duy Pham, Ben Buelow, Ami Ndiaye, James T. Symanowski, Saad Z. Usmani, Katherine Rigby, Myra M. Robinson, Shebli Atrash, David M. Foureau, Fei Guo, Peter M. Voorhees, Shelley Force Aldred, Manisha Bhutani, Marina Leonidas, Elise Tjaden
Publikováno v:
Blood. 132:1940-1940
INTRODUCTION: The human B-Cell maturation antigen (BCMA) is a surface marker that is highly expressed on plasma cells and has been recognized as a novel target in multiple myeloma (MM). TNB-383B is a fully human bispecific monoclonal IgG4 antibody. T
Autor:
Gabriela Chiosis, Saad Z. Usmani
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 11:S77-S81
The heat shock protein 90 (HSP90) family of proteins are ubiquitous molecular chaperones that are intricately involved in folding, activation, maturation, and assembly of many proteins that include essential mediators of signal transduction and cell